about
Hepatitis C virus core protein regulates p300/CBP co-activation function. Possible role in the regulation of NF-AT1 transcriptional activityMolecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamilyThe human natural killer gene complex is located on chromosome 12p12-p13Structure of the human CD94 C-type lectin geneInhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factorDevelopment of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2AA cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides.Gene therapy based in antimicrobial peptides and proinflammatory cytokine prevents reactivation of experimental latent tuberculosis.Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules.The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis.Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement.The hepatitis B virus X protein binds to and activates the NH(2)-terminal trans-activation domain of nuclear factor of activated T cells-1.Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies.Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model.Bioengineered skin humanized model of psoriasis.The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I moleculesCRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa PatientClinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing
P50
Q24304555-83401471-2EB6-4F8A-BA31-7933DA637E6FQ24314332-3D170377-A6B6-4058-ABA6-E47836EDDA65Q28243367-39D74581-7804-4A8B-956B-89D867F960E9Q28262416-9142D033-254C-4ABD-95C6-4D2F8C7788D7Q28277337-C3DCA619-1B23-4013-9F17-77219417BD57Q34358442-600059FB-FA74-4F5A-9AC0-1DC6F4173AADQ36065870-A477FD14-C4C5-4CC6-ADF1-131019F0F775Q40509451-4DE78514-1BD1-41AA-8F0D-33ABBC4F82E0Q40548581-45929209-1EFD-436A-A5E6-8DD3D0218E59Q41373758-48650015-754C-42F1-B1AE-4B62D1A20A00Q43601225-CA152BE3-D436-476B-B314-085E38DA71C2Q45080276-CF464AAD-E99C-47A1-A20C-E8FFF585991EQ45731154-54967F0E-687C-4BAF-9201-5E9521DD9F9FQ49094378-6681F94B-AD53-48B7-9623-0FD120622E7FQ49122682-E05B9BDA-37E6-4487-BDE2-FEA39740D576Q53124380-B82A9535-130F-4DB0-85A5-D3730CE84E60Q57200941-82AB952E-5482-42D1-A7DE-535AD1BBAF17Q64043649-0D79CBC7-17BB-480D-87BF-3BABB346A026Q92727732-0B166745-0E22-48A4-9F27-9F7F7AF101C4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marta Carretero
@ast
Marta Carretero
@en
Marta Carretero
@es
Marta Carretero
@nl
Marta Carretero
@sl
type
label
Marta Carretero
@ast
Marta Carretero
@en
Marta Carretero
@es
Marta Carretero
@nl
Marta Carretero
@sl
prefLabel
Marta Carretero
@ast
Marta Carretero
@en
Marta Carretero
@es
Marta Carretero
@nl
Marta Carretero
@sl
P1053
C-3842-2017
P106
P1153
7006690876
P21
P31
P3829
P496
0000-0001-6152-3102